Literature DB >> 25463602

HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing.

Christoph C Carter1, Gabriel A Wagner2, George K Hightower1, Gemma Caballero3, Pham Phung4, Douglas D Richman5, Sergei L Kosakovsky Pond1, Davey M Smith5.   

Abstract

To better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined associations between viral genetic diversity and the NAb response against a multi-subtype panel of heterologous viruses in a well-characterized, therapy-naïve primary infection cohort. Using next generation sequencing (NGS), we computed sequence-based measures of diversity within HIV-1 env, gag and pol, and compared them to NAb breadth and potency as calculated by a neutralization score. Contemporaneous env diversity and the neutralization score were positively correlated (p=0.0033), as were the neutralization score and estimated duration of infection (EDI) (p=0.0038), and env diversity and EDI (p=0.0005). Neither early env diversity nor baseline viral load correlated with future NAb breadth and potency (p>0.05). Taken together, it is unlikely that neutralizing capability in our cohort was conditioned on viral diversity, but rather that env evolution was driven by the level of NAb selective pressure.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV-1 genetic diversity; Neutralizing antibody; Neutralizing antibody breadth and potency; Next generation sequencing; Viral evolution

Mesh:

Substances:

Year:  2014        PMID: 25463602      PMCID: PMC4259848          DOI: 10.1016/j.virol.2014.10.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  HyPhy: hypothesis testing using phylogenies.

Authors:  Sergei L Kosakovsky Pond; Simon D W Frost; Spencer V Muse
Journal:  Bioinformatics       Date:  2004-10-27       Impact factor: 6.937

2.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

3.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.

Authors:  Simon D W Frost; Terri Wrin; Davey M Smith; Sergei L Kosakovsky Pond; Yang Liu; Ellen Paxinos; Colombe Chappey; Justin Galovich; Jeff Beauchaine; Christos J Petropoulos; Susan J Little; Douglas D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

6.  Maintenance of Nef-mediated modulation of major histocompatibility complex class I and CD4 after sexual transmission of human immunodeficiency virus type 1.

Authors:  C M Noviello; S L Kosakovsky Pond; M J Lewis; D D Richman; S K Pillai; O O Yang; S J Little; D M Smith; J C Guatelli
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

7.  HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response.

Authors:  Anne Piantadosi; Bhavna Chohan; Dana Panteleeff; Jared M Baeten; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection.

Authors:  P Carotenuto; D Looij; L Keldermans; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

10.  Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

Authors:  Iliyana Mikell; D Noah Sather; Spyros A Kalams; Marcus Altfeld; Galit Alter; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

View more
  17 in total

1.  High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.

Authors:  Eric R Weiss; Galit Alter; Javier Gordon Ogembo; Jennifer L Henderson; Barbara Tabak; Yasin Bakiş; Mohan Somasundaran; Manuel Garber; Liisa Selin; Katherine Luzuriaga
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

2.  Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics.

Authors:  Sergio M de Almeida; Michelli F Oliveira; Antoine Chaillon; Indianara Rotta; Clea E Ribeiro; Ana Paula de Pereira; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-09-07       Impact factor: 2.643

3.  Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.

Authors:  Antoine Chaillon; Sara Gianella; Steven M Lada; Josué Perez-Santiago; Parris Jordan; Caroline Ignacio; Maile Karris; Douglas D Richman; Sanjay R Mehta; Susan J Little; Joel O Wertheim; Davey M Smith
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

4.  Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.

Authors:  Sergio M de Almeida; Indianara Rotta; Clea E Ribeiro; Michelli F Oliveira; Antoine Chaillon; Ana Paula de Pereira; Ana Paula Cunha; Marise Zonta; Joao França Bents; Sonia M Raboni; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2017-02-28       Impact factor: 2.643

5.  Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Authors:  V Sanchez-Merino; A Fabra-Garcia; N Gonzalez; D Nicolas; A Merino-Mansilla; C Manzardo; J Ambrosioni; A Schultz; A Meyerhans; J R Mascola; J M Gatell; J Alcami; J M Miro; E Yuste
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

6.  No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.

Authors:  Antoine Chaillon; Masato Nakazawa; Joel O Wertheim; Susan J Little; Davey M Smith; Sanjay R Mehta; Sara Gianella
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

7.  The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection.

Authors:  Valerie Cortez; Bingjie Wang; Adam Dingens; Mitchell M Chen; Keshet Ronen; Ivelin S Georgiev; R Scott McClelland; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2015-07-09       Impact factor: 6.823

8.  Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains.

Authors:  Andrew D Redd; Nicole A Doria-Rose; Joshua A Weiner; Martha Nason; Matthew Seivers; Stephen D Schmidt; Oliver Laeyendecker; Craig Martens; Daniel Bruno; Brandon F Keele; Nagarajan Raju; Ivelin S Georgiev; Susanna L Lamers; Jacquie Astemborski; Gregory D Kirk; John R Mascola; Margaret E Ackerman; Shruti H Mehta; Thomas C Quinn
Journal:  J Infect Dis       Date:  2020-02-18       Impact factor: 7.759

9.  HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.

Authors:  Maria Pernas; Victor Sanchez-Merino; Concepcion Casado; Alberto Merino-Mansilla; Isabel Olivares; Eloisa Yuste; Cecilio Lopez-Galindez
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

10.  Assessment of the Utility of Whole Genome Sequencing of Measles Virus in the Characterisation of Outbreaks.

Authors:  Ana Raquel Penedos; Richard Myers; Besma Hadef; Farah Aladin; Kevin E Brown
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.